Biodexa Pharmaceuticals
BDRX
4 hedge funds and large institutions have $17K invested in Biodexa Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
20% less funds holding
Funds holding: 5 → 4 (-1)
40% less capital invested
Capital invested by funds: $28.1K → $17K (-$11.1K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GI
GAMMA Investing
Foster City,
California
|
+$13.4K |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
+$7.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$21.5K |
| 2 |
Morgan Stanley
New York
|
-$924 |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$319 |
| 4 |
CIM
Contravisory Investment Management
Norwell,
Massachusetts
|
-$53 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GI
1
GAMMA Investing
Foster City,
California
| $10.3K | +$13.4K | +210 | +724% |
|
|
SS
2
SBI Securities
Tokyo,
Japan
| $4.9K | +$7.2K | +113 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $1.72K | -$21.5K | -337 | -89% |
|
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $59 | -$319 | -5 | -83% |
|
|
5
Morgan Stanley
New York
| – | -$924 | -14 | Closed |
|
|
CIM
6
Contravisory Investment Management
Norwell,
Massachusetts
| – | -$53 | -1 | Closed |
|
BDRX Hedge Fund Activity: Q2 2025 in Review
4 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q2 2025, worth a combined $17K — down 40% from $28.1K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BDRX and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was GAMMA Investing, adding an estimated $13.4K. The largest seller was UBS Group, cutting an estimated $21.5K.
- 4 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q2 2025, down from 5 in Q1 2025.
- Funds reported $17K of Biodexa Pharmaceuticals stock for Q2 2025, down 40% quarter-over-quarter.
- 1 fund opened new Biodexa Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of -1 holder.
- The largest Biodexa Pharmaceuticals buyer in Q2 2025 was GAMMA Investing, an estimated $13.4K added.
- The largest Biodexa Pharmaceuticals seller in Q2 2025 was UBS Group, an estimated $21.5K sold.
Based on aggregated 13F filings for Q2 2025.